Defactinib hydrochloride is under clinical development by Verastem and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Defactinib hydrochloride’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 23 Dec 2022 decreased Defactinib hydrochloride’s LoA and PTSR for Ovarian Cancer.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Defactinib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Defactinib hydrochloride overview
Defactinib hydrochloride (VS-6063) is under development for the treatment of pancreatic ductal adenocarcinoma as adjuvant therapy, metastatic uveal melanoma, KRAS-mutated NSCLC, colorectal cancer, malignant pleural mesothelioma, endometrial cancer, prostate cancer, epithelial ovarian cancer, fallopian tube cancer, low-grade serous ovarian cancer, peritoneal cancer, triple negative breast cancer and pancreatic cancer. The drug candidate is administered by oral route. VS-6063 is a selective inhibitor of the FAK family kinases focal adhesion kinase (FAK) and protein tyrosine kinase 2 Beta (PTK-2B). It was also under development for malignant pleural mesothelioma in EU and solid tumors (non-hematologic malignancy).
Verastem is a biopharmaceutical company. It carries out the discovery, development, and commercialization of novel small molecule drugs to treat cancer. The company’s most advanced product candidates include VS-6766, defactinib (VS-6063). Verastem products VS-6766 and defactinib (VS-6063), are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. The pipeline products focused on Raf/MEK inhibition and FAK inhibition. Its service include investigator sponsored trial (IST)program. The company operates in Germany and the US. Verastem is headquartered in Needham, Massachusetts, the US.
Quick View Defactinib hydrochloride LOA Data
|Highest Development Stage|